Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNuvectis Pharma Inc

Nuvectis Pharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
20.66 USD -0.25 ( 1.20%)
Last update at 2026-11-09T15:41:00Z
VOLUME
66187
Market Cap
120.78M

Momentum Score

…

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
19.72
Low
21.09
High
52 Week Price Range
5.85
Low
18.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
20.91
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-170.23%
Net Debt
-19.13M
ROCE
-157.64%
Diluted EPS TTM
-1.50

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -19.09M -12.89M -
Net income -18.79M -12.89M -
Selling general administrative 6.01M 3.35M -
Gross profit -19.09M -12.89M -
Ebit -19.23M -12.89M -0.02M
Ebitda -19.23M -12.89M -
Depreciation and amortization 0.30M 0.00M -
Operating income -19.23M -12.89M -
Other operating expenses 19.23M 12.89M -
Interest expense 0.15M 0.00M 0.00M
Interest income 0.15M 0.00M -
Net interest income 0.15M 0.00M -
Income tax expense -0.30M -0.00M -
Total revenue 0.15M 0.00M -
Total operating expenses 19.23M 12.89M -
Cost of revenue 19.23M 12.89M -
Total other income expense net 0.15M 0.00M -
Net income from continuing ops -19.23M -12.89M -
Net income applicable to common shares -19.09M -12.89M -0.02M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 19.18M 20.41M 6.66M 6.66M
Other current assets 0.06M 0.41M 0.09M 0.09M
Total liab 6.98M 6.19M 17.66M 0.01M
Total stockholder equity 12.20M 14.22M -11.01M -0.01M
Deferred long term liab - - 0.82M -
Other current liab 4.21M 3.28M 1.36M -
Common stock 17768.82M 14752.40M - -
Capital stock 0.00M 0.00M 0.00M 0.00M
Retained earnings -54.24M -31.98M -12.90M -0.01M
Other assets - - 0.82M -
Cash 19.13M 19.99M 5.74M 5.74M
Total current liabilities 6.98M 6.19M 2.42M 0.01M
Net debt -19.13M -19.99M -5.74M -
Other stockholder equity -17702.38M 25.80M -13.35M -
Total current assets 19.18M 20.41M 5.83M 5.83M
Net tangible assets - 14.22M -11.01M -0.00M
Accounts payable 2.77M 2.91M 1.06M 0.01M
Accumulated other comprehensive income - -14752.40M - -
Retained earnings total equity - -31.98M - -
Non currrent assets other - - 0.82M -
Non current assets total 0.00M 0.00M 0.82M 0.82M
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments 0.00M 0.00M -
Change to liabilities 4.14M 1.58M 0.02M
Total cash from financing activities 27.81M 15.25M 15.25M
Change to operating activities -0.32M -0.09M -0.09M
Net income -19.09M -12.89M -0.02M
Change in cash 14.25M 5.74M 5.74M
Begin period cash flow 5.74M 0.00M -
End period cash flow 19.99M 5.74M -
Total cash from operating activities -13.56M -9.50M -9.50M
Issuance of capital stock 31.88M 15.25M -
Sale purchase of stock 27.81M - -
Other cashflows from financing activities -4.07M 15.25M -4.07M
Change to netincome 1.71M 1.89M 1.89M
Capital expenditures 0.00M 0.00M 0.00M
Cash flows other operating -0.32M - -
Cash and cash equivalents changes 14.25M - -
Change in working capital 3.82M 1.49M -
Stock based compensation 1.71M 1.89M -
Free cash flow -13.56M -9.50M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVCT
Nuvectis Pharma Inc		 -0.25
1.20%		 20.66 - - - 10.15 -4.57
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Nuvectis Pharma Inc

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

1 Bridge Plaza, Fort Lee, NJ, United States, 07024

201 614 3150

https://www.nuvectis.com

13

Name Title Year Born
Mr. Ron Bentsur M.B.A. Co-Founder, Chairman, CEO & Pres 1966
Dr. Enrique Poradosu Ph.D. Co-Founder, Exec. VP, Chief Scientific & Bus. Officer 1967
Mr. Shay Shemesh Co-Founder, EVP, Chief Devel. & Operations Officer 1984
Mr. Michael Carson CPA VP of Fin. 1976
Mr. Ron Bentsur M.B.A. Co-Founder, Chairman, CEO & President 1966
Dr. Enrique Poradosu Ph.D. Co-Founder, Executive VP, Chief Scientific & Business Officer 1967
Mr. Shay Shemesh Co-Founder, Executive VP, Chief Development & Operations Officer 1984
Mr. Michael Carson CPA Vice President of Finance 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…